Opexa Therapeutics Inc. (NASDAQ:OPXA) shot up 5% during mid-day trading on Monday . The stock traded as high as $4.47 and last traded at $4.41, with a volume of 59,879 shares changing hands. The stock had previously closed at $4.20.

Several brokerages have issued reports on OPXA. Aegis reissued a “buy” rating and issued a $11.00 price target on shares of Opexa Therapeutics in a report on Monday, August 15th. Chardan Capital reissued a “buy” rating and issued a $6.00 price target on shares of Opexa Therapeutics in a report on Sunday, August 14th. Maxim Group reissued a “buy” rating and issued a $18.00 price target on shares of Opexa Therapeutics in a report on Friday, August 12th. Finally, Zacks Investment Research lowered shares of Opexa Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 20th.

The firm has a 50 day moving average of $4.18 and a 200-day moving average of $3.00. The stock’s market cap is $31.23 million.

Opexa Therapeutics (NASDAQ:OPXA) last released its earnings results on Thursday, August 11th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.23) by $0.07. During the same quarter last year, the company earned ($0.56) EPS. On average, equities research analysts expect that Opexa Therapeutics Inc. will post ($1.12) earnings per share for the current year.

Opexa Therapeutics, Inc (Opexa) is a biopharmaceutical company. The Company is engaged in the development of a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on its T-cell technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.